Abstract:Objectives: Invasive pneumococcal disease (IPD) and a variety of clinical syndromes caused by pneumococci, such as acute otitis media (AOM), acute sinusitis (AS), and community-acquired pneumonia (CAP), cause a substantial burden on healthcare systems. Few studies have explored the short-term financial burden of pneumococcal disease after the 13-valent pneumococcal conjugate vaccine (PCV13) introduction in the infant immunization programs. This population-based study evaluated changes in costs associated with healthcare utilization for pneumococcal disease after the PCV13 introduction in the infant immunization program in British Columbia, Canada. Methods: Individuals with pneumococcal disease were identified using provincial administrative data for the 2000 to 2018 period. Total direct healthcare costs were determined using case-mix methodology for hospitalization and fee-for-service codes for outpatient visits and medications dispensed. Costs were adjusted to 2018 Canadian dollars. Changes in the annual healthcare costs were evaluated across vaccine eras (pre-PCV13, 2000-2010; PCV13, 2011-2018) using generalized linear models, adjusting for the 7-valent pneumococcal conjugate vaccine program (2004-2010). Results: During the 19-year study period, pneumococcal disease resulted in 6.3 million cases among 85 million total patient-years, resulting in total healthcare costs of $7.9 billion. More than 6.2 million cases were treated in outpatient setting, costing $0.65 billion (8% of total costs associated with pneumococcal disease treatment), whereas 370 000 hospitalized cases were 3% of all cases, which accrued $7.25 billion (92% of total costs) in costs. Healthcare costs for all studied infections nearly doubled over the study period from $248 million in 2000 to $476 million in 2018 (P = .003). In contrast, there were large declines in total annual costs in the PCV13 era for IPD (adjusted relative rate (aRR) 0.73; 95% confidence interval [CI] 0.56-0.95; P = .032), AOM (aRR 0.70; 95% CI 0.59-0.83; P = .001), and AS (aRR 0.68; 95% CI 0.54-0.85; P = .004) compared with the pre-PCV13 era. Total costs increased marginally in the PCV13 era for all-cause CAP (aRR 1.04; 95% CI 0.94-1.15; P = .484). Conclusions: This study confirms a temporal association in declining economic burden for IPD, AOM, and AS after the PCV13 introduction. Nevertheless, the total economic burden continues to be high in the PCV13 era, mainly driven by increasing CAP costs.

Changing trends of acute otitis media bacteriology in central Israel in the pneumococcal conjugate vaccines era

Epidemiology of Acute Otitis Media in the Postpneumococcal Conjugate Vaccine Era

Incidence of acute otitis media from 2003 to 2019 in children ≤ 17 years in England

Incidence of Acute Otitis Media in Children in the United States Before and after the Introduction of 7- and 13-Valent Pneumococcal Conjugate Vaccines During 1998–2018

Emerging Clinical Features of Acute Mastoiditis in Israel: A Registry Based Cohort

The impact of pneumococcal conjugate vaccine-13 on the incidence of pediatric community-acquired bacteremia

Anticipated Effects of Higher-valency Pneumococcal Conjugate Vaccines on Colonization and Acute Otitis Media

Initial effects of the National PCV7 Childhood Immunization Program on adult invasive pneumococcal disease in Israel

Impact of pneumococcal conjugate vaccines on childhood otitis media in the United Kingdom

Influence of the Protein-conjugated Pneumococcal Vaccine (PCV7) and the Newly Developed Antimicrobials on the Incidence of Acute Otitis Media and the Frequency of Myringotomy

Clinical and economic burden of acute otitis media caused by Streptococcus pneumoniae in European children, after widespread use of PCVs–A systematic literature review of published evidence

Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010

Development of pneumococcal mastoiditis due to multidrug-resistant serotype 19A despite three doses of 13-valent pneumococcal vaccine

Pneumococci isolated from children in community-based practice differ from isolates identified by population and laboratory-based invasive disease surveillance

Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review

Assessing the utilization of antimicrobial agents in pediatric pneumonia during the era of the 13-valent pneumococcal conjugate vaccine: A retrospective, single-center study

Nasopharyngeal colonization by Streptococcus pneumoniae and other common bacteria eight years following introduction of pneumococcal conjugate vaccine in rural South African children ≤5 years old.

Etiology and epidemiology of children with acute otitis media and spontaneous otorrhea in Suzhou, China.

Impact of 10-valent pneumococcal conjugate vaccine on the epidemiology of otitis media with otorrhea among Bangladeshi children

Healthcare Costs for Pneumococcal Disease in the Era of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine: A Population-Based Study

Effect of Pneumococcal Conjugate Vaccine on Prevalence of Otitis Media with Effusion among Children in Vietnam.